Skip to main content
. 2020 Apr 4;12(4):878. doi: 10.3390/cancers12040878

Figure 3.

Figure 3

CHK1 expression, activation by rucaparib, and inhibition by PF-477736 in BRCA2 mutant and corrected cells. Cells were exposed for 24 h to DMSO, rucaparib, or rucaparib and PF-477736 and analysed for pCHKS345, CHK1, and pCDK1Tyr15. Vinculin was used as a loading control for pCHKS345, CHK1, pCDK1Tyr15 and CDK1, and GAPDH was used as the loading control for CHK1S296 (a) Western blot from a single representative experiment. (b) Densitometry was calculated using Syngene software of CHK1 expression normalised to Vinculin. (c) Normalised densitometry of phosphorylated CHK1 and CDK1. Data are the mean and standard deviation of three individual experiment.